全文获取类型
收费全文 | 229405篇 |
免费 | 12184篇 |
国内免费 | 6455篇 |
专业分类
耳鼻咽喉 | 2746篇 |
儿科学 | 8438篇 |
妇产科学 | 3725篇 |
基础医学 | 16436篇 |
口腔科学 | 4165篇 |
临床医学 | 27054篇 |
内科学 | 39376篇 |
皮肤病学 | 3059篇 |
神经病学 | 10806篇 |
特种医学 | 12195篇 |
外国民族医学 | 22篇 |
外科学 | 40018篇 |
综合类 | 20640篇 |
现状与发展 | 25篇 |
预防医学 | 14865篇 |
眼科学 | 4398篇 |
药学 | 24239篇 |
86篇 | |
中国医学 | 4487篇 |
肿瘤学 | 11264篇 |
出版年
2023年 | 1909篇 |
2022年 | 3798篇 |
2021年 | 9162篇 |
2020年 | 5362篇 |
2019年 | 11290篇 |
2018年 | 5938篇 |
2017年 | 5197篇 |
2016年 | 7154篇 |
2015年 | 9969篇 |
2014年 | 18750篇 |
2013年 | 16129篇 |
2012年 | 19662篇 |
2011年 | 16474篇 |
2010年 | 15160篇 |
2009年 | 14709篇 |
2008年 | 13307篇 |
2007年 | 13276篇 |
2006年 | 11198篇 |
2005年 | 7458篇 |
2004年 | 3810篇 |
2003年 | 3274篇 |
2002年 | 2567篇 |
2001年 | 2081篇 |
2000年 | 1825篇 |
1999年 | 1176篇 |
1998年 | 1571篇 |
1997年 | 1410篇 |
1996年 | 1173篇 |
1995年 | 1244篇 |
1994年 | 1193篇 |
1993年 | 901篇 |
1992年 | 1109篇 |
1991年 | 987篇 |
1990年 | 1032篇 |
1989年 | 1004篇 |
1988年 | 929篇 |
1987年 | 820篇 |
1986年 | 668篇 |
1985年 | 1579篇 |
1984年 | 1736篇 |
1983年 | 1252篇 |
1982年 | 1338篇 |
1981年 | 1323篇 |
1980年 | 1142篇 |
1979年 | 981篇 |
1978年 | 755篇 |
1977年 | 759篇 |
1976年 | 660篇 |
1974年 | 454篇 |
1973年 | 432篇 |
排序方式: 共有10000条查询结果,搜索用时 145 毫秒
61.
垂体腺瘤(PA)通常引起性腺轴的损害,导致女性患者的生育能力下降。妊娠可使垂体增大,而性腺轴的激素分泌也随之发生相应改变。因此,对患有PA的妊娠妇女的规范化管理显得尤为重要。2021年8月,欧洲内分泌学会(ESE)发布了关于妊娠期功能性和无功能性PA的临床指南,该指南从腺瘤的大小、位置和有无内分泌功能方面,描述了从妊娠前到分娩后诊断、治疗的时机和选择。本文在ESE指南的基础上,对该指南进行了解读,总结了该指南的要点,以期结合中国的临床经验及患者特点,为临床医师管理此类患者提供具有实践意义的指导意见。 相似文献
62.
63.
64.
《Patient education and counseling》2022,105(10):3110-3115
IntroductionThe Knowledge of Genome Sequencing (KOGS) questionnaire was recently developed to measure knowledge of genomic sequencing (GS), with preliminary psychometric data supporting its reliability and validity. The aim of this study was to test the reliability and validity of the KOGS in a larger sample, and to confirm its utility in a cancer setting.MethodsThe Genetic Cancer Risk in the Young (RisC) study recruits participants with a personal history of cancer, to investigate heritable cancer causes and future cancer risk using germline GS. Participants (n = 261) in a psychosocial substudy of RisC completed a questionnaire after consent to RisC but before GS, including the KOGS, the Intolerance of Uncertainty Scale, the Chew health literacy scale and items assessing demographic and disease variables. Confirmatory factor analysis (CFA), Cronbach alpha and correlational analyses were undertaken.ResultsThe CFA testing a single-factor model yielded a good model fit, χ2/df = 2.43, comparative fit index (CFI) = 0.97, root mean square error of approximation (RMSEA) = 0.07 and weighted mean root square (WRMR) = 1.03. Factor loadings of all items were above 0.60 and ranged between.66 and.93. The single factor score demonstrated excellent internal consistency (α = 0.82). KOGS scores were significantly associated with health literacy (r = 0.23, p < .001), having a university education [t(258) = ?4.53, p < .001] and having a medical or science background [t(259) = ?3.52, p < .001] but not with speaking a language other than English at home, time since diagnosis, previous genetic counselling/testing or intolerance of uncertainty.DiscussionThis study confirmed a single-factor structure for the KOGS, and its reliability and validity in a cancer population. Associations with measures of health literacy and education were significant and positive as expected, supporting the KOG’s construct validity. Previous genetic counselling may not be sufficient to provide specific knowledge of GS. 相似文献
65.
66.
《Drug discovery today》2022,27(1):246-256
Bromodomain-containing protein 4 (BRD4) is emerging as a therapeutic target that acts synergistically with other targets of small-molecule drugs in cancer. Therefore, the discovery of potential new dual-target inhibitors of BRD4 may be a promising strategy for cancer therapy. In this review, we highlight a series of strategies to design therapeutic dual-target inhibitors of BRD4 that focus on the synergistic functions of this protein. Drug combinations that exploit synthetic lethality, protein–protein interactions, functional complementarity, and blocking of resistance mechanisms could ultimately overcome the barriers inherent to the development of BRD4 inhibitors as future cancer drugs. 相似文献
68.
69.
70.
《Cirugía espa?ola》2022,100(11):709-717
ObjectiveMost evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma.MethodMulticentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS).ResultsA total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse.including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed.ConclusionThe present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients. 相似文献